Investigational antibody-drug conjugates for hematological malignancies

By Polson Andrew G   Ho William Y   Ramakrishnan Vanitha  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 1, 2011-01 ,pp. : 75-85

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal antibody–drug conjugates

By Hamann Philip R  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 9, 2005-09 ,pp. : 1087-1103

Informa Healthcare

Access to resources Recommend Favorite

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

By Haddish-Berhane Nahor   Shah Dhaval   Ma Dangshe   Leal Mauricio   Gerber Hans-Peter   Sapra Puja   Barton Hugh   Betts Alison  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 40, Iss. 5, 2013-10 ,pp. : 557-571

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

By Goss G.   Hirte H.   Miller W.   Lorimer I.   Stewart D.   Batist G.   Parolin D.   Hanna P.   Stafford S.   Friedmann J.   Walsh W.   Mathews S.   Douglas L.   Seymour L.  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 147-155

Springer Publishing Company

Access to resources Recommend Favorite

Drug Delivery and Transport to Solid Tumors

By Jang Seong Hoon   Wientjes M. Guillaume   Lu Dan   Au Jessie L.-S.  

Pharmaceutical Research, Vol. 20, Iss. 9, 2003-09 ,pp. : 1337-1350

Springer Publishing Company

Access to resources Recommend Favorite